Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kevin S. Windsor"'
Autor:
Marianna Zavodovskaya, Jorge Chaves, JieJane Liu, Carrie Baker Brachmann, Jordan Berlin, Michael S. Gordon, Sunil Sharma, Manish R. Patel, Zev A. Wainberg, Pankaj Bhargava, Dung Thai, Kevin S Windsor, Johanna C. Bendell, Saad A. Khan, Manish A. Shah, Alexander Starodub
Publikováno v:
The oncologist, vol 25, iss 11
Oncologist
Oncologist
Background Matrix metalloproteinase 9 (MMP9) expression in the tumor microenvironment is implicated in multiple protumorigenic processes. Andecaliximab (GS-5745), a monoclonal antibody targeting MMP9 with high affinity and selectivity, was evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::debc71132541d499dc85a682ed9c418e
https://doi.org/10.1634/theoncologist.2020-0474
https://doi.org/10.1634/theoncologist.2020-0474
Autor:
Sunil Sharma, Johanna C. Bendell, Xi Huang, Jeffrey A. Silverman, Manish A. Shah, Zev A. Wainberg, Michael S. Gordon, Victoria Smith, Heinz-Josef Lenz, Jorge Chaves, Gregory S. Vosganian, Kevin S Windsor, Julia D. Maltzman, Jordan Berlin, Carrie Baker Brachmann, Manish R. Patel, Alexander Starodub
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 16
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 16
Purpose: Matrix metalloproteinase-9 (MMP9) is implicated in protumorigenic processes. Andecaliximab (GS-5745, a monoclonal antibody targeting MMP9) was evaluated as monotherapy and in combination with mFOLFOX6. Patients and Methods: Three dosages of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07fbaf74d540a5d51803927dcbfbd451
https://europepmc.org/articles/PMC7496223/
https://europepmc.org/articles/PMC7496223/
Autor:
Stephanie A. Gregory, Marc Monte, Robert C. Hermann, Akiko Chai, Kevin S. Windsor, Paul Richards, Michael Brewster, Shaker R. Dakhil, Marshall T. Schreeder, Deborah Hurst
Publikováno v:
Leukemia & Lymphoma. 55:2335-2340
This phase III, multicenter, single-arm trial investigated the impact of 90 min rituximab infusions on infusion-related reactions (IRRs) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients received s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbe5e83d2372623e9aad4b6ba1ee2d92
https://doi.org/10.3109/10428194.2013.877135
https://doi.org/10.3109/10428194.2013.877135